Preview of EULAR 2019 Abstracts Save
EULAR 2019 begins today in Madrid and features over 2000 presentations. After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.
EULAR will be rolling out many new “guidelines” reports including those addressing rheumatoid arthritis (RA) treatment; immune-related adverse events with checkpoint inhibitors, Sjogrens syndrome and more.
Late-breaking abstracts will be presented on Saturday morning (June 15th) and will include reports on filgotinib (Finch3), secukinumab (FUTURE 5), HLA-DRB1 alleles and responses to Abatacept or Adalimumab, Ultra-low dose rituximab and more.
Here are some abstracts I’ll be watching (with links to EULAR Abstract site). Which of these interests you?
|
Abstract |
Title |
Comment |
|
Two regimens of Rituximab in Scleroderma associated interstitial lung disease |
Appears to improve Lung function |
|
|
KAWAKINRA study: A pilot trial of anakinra in patients with IVIg-resistant Kawasaki disease |
Rare disorder with good results in refractory disease. Dosing issues? |
|
|
Randomized, double blind, placebo controlled trial of Steroids in Hand OA |
Looks like it works? But what about adverse effects? |
|
|
Riociguat in SSc associated ILD |
Anti-fibrotic drug shows some benefit in SSc lung disease |
|
|
|
TOLEDEO study – Spacing ABA or TCZ to find the lowest effective dose in RA patients |
Looks like less drug therapy carried a high risk of failure |
|
Registry data on long-term outcomes and treatment efficacy in the TRAPS patients |
IL-1 inhibitors much more effective than etanercept |
|
|
Statins reduce relapse rates in Takayasu arteritis |
A novel adjunctive therapy? |
|
|
Fenebrutinib vs. Adalimumab in RA |
BTK inhibitor works in MTX- & TNF-IR patients |
|
|
Implated Vagal nerve stimulator in rheumatoid arthritis |
Only 14 patients but novel, and looks effective |
|
|
Tildrakizumab in active PsA patients |
Data on 3rd IL-23 inhibitor |
|
|
Maxmize Study: Secukinumab on Axial Manifestations in Psoriatic arthritis |
Secukinumb works on the Axial outcomes of PsA pts with Spondylitis |
|
|
Measures of psoriasis severity and the risk of PsA |
Skin severity predicts risk of PsA |
|
|
Characterization of psoriatic arthritis and nail psoriasis |
CORRONA - Nail disease predicts worse disease activity |
|
|
Ultrasound application in Extracranial GCA |
Axillary US correlates with PET findings |
|
|
EULAR recommendations for the management of irAE |
One of many EULAR recommendations at this meeting |
|
|
EULAR Recommendations for the Management of Sjogrens |
|
ADD THE FIRST COMMENT
Disclosures
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.